Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Fatima M. Izhaeva; Olga Popova; Tatiana A Ozharovskaya; I. B. Esmagambetov; I. A. FAVORSKAYA; Denis I. Zrelkin; Daria V. Voronina; Dmitry N. Shcherbinin; А. С. Семихин; Yana V. Simakova; Elizaveta A. Tokarskaya; Nadezhda L. Lubenets; Д.А. Егорова; М. М. Шмаров; Н. А. Никитенко; Morozova Lf; Е. А. Smolyarchuk; Е. V. Kryukov; V. F. Babira; Sergei V. Borisevich; Boris S. Naroditsky; Gintsburg Al; Denis Y. Logunov; Inna V. Dolzhikova; Olga V. Zubkova; Amir I. Tukhvatulin; Dmitry V. Shcheblyakov; Alina S. Dzharullaeva; Daria M. Grousova; Alina S. Erokhova; Anna V. Kovyrshina; А Г Ботиков

doi:10.1016/s0140-6736(20)31866-3

Keywords

ImmunogenicityCoronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineHeterologousPrime (order theory)Coronavirus InfectionsVector (molecular biology)ImmunologyRecombinant DNAInternal medicineBiologyAntigenMathematicsInfectious disease (medical specialty)Disease

Affiliated Institutions

Related Publications

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov , Inna V. Dolzhikova , Dmitry V. Shcheblyakov +28 more

A heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in pa...

2021 The Lancet 1799 citations

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Bindu Bennet , Jayanthi Wolf , Rodrigo Laureano +1 more

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an ur...

2020 Toxicologic Pathology 47 citations

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Mimi Guebre‐Xabier , Nita Patel , Jing-Hui Tian +10 more

There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective effi...

2020 Vaccine 238 citations

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas , Frederick J. Angulo , John M. McLaughlin +12 more

Following the emergency use authorisation of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the Ministry of Healt...

2021 The Lancet 1722 citations

Publication Info

Year: 2020
Type: article
Volume: 396
Issue: 10255
Pages: 887-897
Citations: 1109
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1109

OpenAlex

Cite This

APA Style

                            
                                
                                    Fatima M. Izhaeva, 
                                
                                    Olga Popova, 
                                
                                    Tatiana A Ozharovskaya
                                
                                et al.
                            
                            (2020). 
                            Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. 
                            The Lancet
                            , 396
                            (10255)
                            , 887-897.
                            https://doi.org/10.1016/s0140-6736(20)31866-3
                        

Identifiers

DOI: 10.1016/s0140-6736(20)31866-3